Abstract
Purpose :
Comparison of the success rate of PreserfloTM MicroShunt implantation in glaucoma patients with and without a condition after filtering surgery or vitrectomy.
Methods :
90 eyes of 79 patients with glaucoma who underwent PreserfloTM MicroShunt surgery between January 2022 and November 2023 were recruited. 45 eyes of patients with primary open-angle glaucoma, 41 eyes with secondary open-angle glaucoma, 3 eyes with congenital glaucoma and 1 eye with chronic angle-closure glaucoma. Outcome parameters were intraocular pressure (IOP) ≤ 15 mmHg app. without antiglaucomatous local therapy, the occurrence of postoperative complications and the performance of reoperations. The statistical analysis was performed using SPSSTM Statistics 28, Mann-Whitney U test.
Results :
In group (A) with condition after filtering surgery/after vitrectomy (N=22), mean IOP [mmHg appl.] was 22.59±12.00 preoperatively, 9.50±4.67 on the first postoperative day, 10.52±3.37 after 1 month, 10.33±3.27 after 3 months, 11.79±3.45 after 6 months, 15.24±9.12 after 9 months, 11.50±2.74 after 12 months, and in group (B) without condition after the above-mentioned surgery (N=68) mean IOP was 22.56±8.36 preoperatively, 9.03±4.46 on the first postoperative day, 11.58±3.59 after 1 month, 12.40±4.05 after 3 months, 13.32±3.74 after 6 months, 13.74±3.99 after 9 months and 13.35±5.08 after 12 months. Target pressure was reached in (A) after 1 month 81.0% of patients, after 3 months 77.8%, after 6 months 85.7% and in (B) after 1 month 77.6%, after 3 months 70.2%, after 6 months 58.0%. Mean follow-up time was 12±5 months. There was no significant difference in IOP values between the two groups at any time of follow-up. The number of patients with complications and treatment failure was comparable between the groups and was low overall.
Conclusions :
PreserfloTM MicroShunt implantation may also be an option for lowering intraocular pressure in patients with complex initial conditions. Patients should continue to be followed up to generate long-term data on the success rate.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.